| Literature DB >> 35968235 |
Chao Dong1,2,3, Jiawei Li1,2, Ming Zhao1,2, Lin Chen3, Xiaochen Zhai1,2, Lingling Song1,2, Jin Zhao1,2, Qiang Sun1,2, Jie Wu1,2, Xiaolu Xie4.
Abstract
Panax notoginseng saponins (PNS), bioactive compounds, are commonly used to treat ischemic heart and cerebral diseases in China and other Asian countries. Most previous studies of PNS have focused on the mechanisms underlying their treatment of ischemic cardiovascular diseases but not cerebral ischemic diseases. This study sought to explore the pharmacological mechanisms underlying the effectiveness of PNS in treating cerebral ischemic diseases. Different experimental cerebral ischemia models (including middle cerebral artery occlusion (MCAO) and the blockade of four arteries in rats, collagen-adrenaline-induced systemic intravascular thrombosis in mice, thrombosis of carotid artery-jugular vein blood flow in the bypass of rats, and hypoxia tolerance in mice) were used to investigate the mechanisms underlying the actions of PNS on cerebral ischemia. The results indicated that (1) PNS improved neurological function and reduced the cerebral ischemia infraction area in MCAO rats; (2) PNS improved motor coordination function in rats with complete cerebral ischemia (blockade of four arteries), decreased Ca2+ levels, and ameliorated energy metabolism in the brains of ischemia rats; (3) PNS reduced thrombosis in common carotid artery-jugular vein blood flow in the bypass of rats; (4) PNS provided significant promise in antistroke hemiplegia and hypoxia tolerance in mice. In conclusion, PNS showed antagonistic effects on ischemic stroke, and pharmacological mechanisms are likely to be associated with the reduction of cerebral pathological damage, thrombolysis, antihypoxia, and improvement in the intracellular Ca2+ overload and cerebral energy metabolism.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35968235 PMCID: PMC9371884 DOI: 10.1155/2022/4281483
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Figure 1PNS reduce the cerebral infarction area and improve neurological function in MCAO rats. (a) Representative TTC staining images of the coronal sections of rats in each group after MCAO. (b) Cerebral infarction area ratios of the rats in each group. (c) Results of functional neurobehavioral scoring. PNS: Panax notoginseng saponins; MCAO: middle cerebral artery occlusion; SO: sham-operated group; TTC: triphenyl tetrazolium chloride. The data were presented as means ± SD (n = 10). Statistical comparisons were evaluated using one-way ANOVA with the Newman–Keuls post hoc test. ∗P < 0.05 and ∗∗P < 0.01 compared with the MCAO model group.
Figure 2PNS increase the coordination function in cerebral ischemia rats. (a) Average maximum angles at which rats slipped down from an inclined smooth plane. (b) Cerebral index of the four artery blocked rats. PNS: Panax notoginseng saponins; SO: sham-operated group. The data were presented as means ± SD (n = 10 or 9). Statistical comparisons were evaluated using one-way ANOVA with the Newman–Keuls post hoc test. ∗∗P < 0.01 compared with the ischemia model group.
Effects of PNS on brain tissue metabolites in cerebral ischemic rats subjected to four-vessel occlusion.
| Group | n | Dose (mg/kg) | Lactic acid ( | FFA ( | ATP ( | Phosphocreatine ( | Ca2+ ( |
|---|---|---|---|---|---|---|---|
| SO | 10 | 9.13 ml | 7.60 ± 0.43∗∗ | 0.036 ± 0.006∗∗ | 2.87 ± 0.16∗∗ | 2.21 ± 0.27∗∗ | 40.88 ± 3.34∗∗ |
| Ischemia model | 10 | 9.13 ml | 21.08 ± 1.59 | 0.091 ± 0.008 | 0.39 ± 0.09 | 1.06 ± 0.20 | 65.83 ± 2.52 |
| Low-dose PNS | 10 | 18.30 | 20.99 ± 1.39 | 0.090 ± 0.006 | 0.40 ± 0.08 | 1.20 ± 0.16 | 63.96 ± 3.43 |
| Middle-dose PNS | 10 | 36.50 | 19.64 ± 1.35 | 0.082 ± 0.006∗ | 0.49 ± 0.10∗ | 1.41 ± 0.12∗∗ | 59.79 ± 2.65∗∗ |
| High-dose PNS | 10 | 73.00 | 15.69 ± 1.07∗∗ | 0.070 ± 0.007∗∗ | 0.72 ± 0.12∗∗ | 1.55 ± 0.12∗∗ | 54.98 ± 3.06∗∗ |
PNS: Panax notoginseng saponins; FFA: free fatty acid; ATP: adenosine triphosphate; SO: sham-operated; data were presented as means ± SD; ∗P < 0.05 and ∗∗P < 0.01 compared with ischemia model.
Figure 3PNS inhibit acute systemic intravascular thromboembolism induced by collagen-adrenaline in mice. (a) Time from collagen-adrenaline injection to hemiplegia of mice. The results were presented as the percentage of normal mice as a function of time. (b) Number of hemiplegic mice induced by collagen-adrenaline within 15 min. P < 0.05 and ∗∗P < 0.01 (n = 12, χ2 test) compared with the thrombosis model group. (c) Time from collagen-adrenaline injection to the death of mice. The results were presented as the percentage of mice alive as a function of time. (d) Number of dead mice within 5 min. ∗P < 0.05 (n = 12, χ2 test) compared with the thrombosis model group. PNS: Panax notoginseng saponins.
Figure 4PNS inhibit arteriovenous (AV) shunt thrombosis in rats. Thrombosis was formed in common carotid artery-jugular vein blood flow in the bypass, and the inset shows the thrombosis inhibition rate of each PNS-treated group. The data were presented as means ± SD (n = 10). Statistical comparisons were evaluated using one-way ANOVA with the Newman–Keuls post hoc test. ∗∗P < 0.01 compared with the thrombosis model group. PNS: Panax notoginseng saponins.
Figure 5PNS prolong the hypoxia tolerance time in mice. The hypoxia tolerance time was recorded from when a mouse was sealed in the jar to its death. The data were presented as means ± SD (n = 10). Statistical comparisons were evaluated using one-way ANOVA with the Newman–Keuls post hoc test. ∗P < 0.05 compared with the hypoxia model group. PNS: Panax notoginseng saponins.